Testing effectiveness (Phase 2)Active Not RecruitingNCT03213652
What this trial is testing
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Who this might be right for
Advanced Malignant Solid NeoplasmMalignant Solid NeoplasmRecurrent Ependymoma+30 more
National Cancer Institute (NCI) 13